AVITA Medical (NASDAQ:RCEL) Now Covered by Analysts at D. Boral Capital

D. Boral Capital began coverage on shares of AVITA Medical (NASDAQ:RCEL - Free Report) in a research report report published on Tuesday, Marketbeat reports. The firm issued a buy rating and a $25.00 target price on the stock.

Separately, Piper Sandler reissued a "neutral" rating and set a $12.00 price objective (up previously from $9.00) on shares of AVITA Medical in a report on Friday, November 8th.

AVITA Medical Stock Performance

Shares of RCEL stock traded up $1.16 during trading hours on Tuesday, reaching $12.91. 175,749 shares of the company's stock were exchanged, compared to its average volume of 174,623. The business has a fifty day moving average price of $11.95 and a 200-day moving average price of $10.24. The stock has a market capitalization of $338.47 million, a P/E ratio of -5.79 and a beta of 1.60. The company has a quick ratio of 3.37, a current ratio of 3.73 and a debt-to-equity ratio of 3.48. AVITA Medical has a fifty-two week low of $7.51 and a fifty-two week high of $18.93.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.21). The company had revenue of $19.55 million during the quarter, compared to the consensus estimate of $19.65 million. AVITA Medical had a negative net margin of 95.47% and a negative return on equity of 194.69%. During the same period last year, the company earned ($0.34) earnings per share. Analysts predict that AVITA Medical will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On AVITA Medical

Several large investors have recently modified their holdings of RCEL. Huntington National Bank bought a new stake in shares of AVITA Medical in the 3rd quarter worth about $32,000. FMR LLC boosted its position in AVITA Medical by 126.9% in the third quarter. FMR LLC now owns 4,248 shares of the company's stock valued at $46,000 after buying an additional 2,376 shares in the last quarter. Quest Partners LLC grew its stake in AVITA Medical by 269.4% during the third quarter. Quest Partners LLC now owns 7,520 shares of the company's stock worth $81,000 after buying an additional 5,484 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of AVITA Medical during the second quarter worth approximately $86,000. Finally, Rhumbline Advisers raised its stake in shares of AVITA Medical by 13.9% in the second quarter. Rhumbline Advisers now owns 36,530 shares of the company's stock valued at $289,000 after acquiring an additional 4,463 shares during the last quarter. 27.66% of the stock is currently owned by institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.